Ambispective cohort studies combine retrospective and prospective data collection to provide a comprehensive understanding of treatment outcomes over time. This hybrid design offers several advantages, particularly in real-world settings where long-term patient follow-up is essential. However, integrating historical data with ongoing observations presents methodological challenges, including selection and temporal biases, missing data, confounding variables, and inconsistencies across data sources. This review outlines key statistical considerations for designing and analyzing ambispective studies. Challenges such as selection bias are addressed using methods such as propensity score matching and inverse probability weighting, while missing data are managed through multiple imputation. Time-dependent variables and confounders are tackled using Cox models, marginal structural models, and mixed-effects models. Techniques such as joint modeling, landmark analysis, and Bayesian frameworks help strengthen causal inference and account for temporal heterogeneity. A structured literature review was conducted across PubMed, Scopus, and Web of Science using predefined keywords related to ambispective design and statistical methods. Studies were selected based on relevance to real-world data/real-world evidence and the presence of statistical approaches to overcome design-related challenges. Data were extracted on study objectives and then thematically synthesized. This review highlights the importance of a robust statistical analysis plan, interdisciplinary collaboration, and methodological rigor. When appropriately designed and analyzed, ambispective studies offer a powerful framework for generating reliable, real-world insights to inform clinical and policy decisions.
Researchers seeking to understand the long-term effects of a particular treatment often face challenges when relying solely on either retrospective or prospective data. To overcome these limitations, they may adopt an ambispective cohort study, a hybrid approach that integrates both past records and ongoing patient monitoring. This method allows for a comprehensive assessment of treatment effects over time by capturing both historical exposure data and future outcomes. The study begins with a retrospective phase, where researchers analyze historical data from hospital records, electronic databases, and patient interviews. This phase helps establish baseline characteristics, including demographics, medical history, disease progression, and prior treatment regimens. By identifying existing patterns in disease management before the formal study period begins, researchers can gain valuable insights into patient outcomes and potential confounders. Once this foundation is established, the study transitions into a prospective phase, where patients are actively followed over time. Researchers track key variables such as treatment adherence, symptom progression, medication effects, and potential adverse events. This real-time monitoring enables a dynamic assessment of treatment responses, providing a more complete understanding of long-term health outcomes. By combining retrospective insights with prospective follow-up, an ambispective cohort study enhances the reliability and depth of clinical research, offering a more holistic evaluation of treatment effectiveness and safety. However, conducting an ambispective cohort study is not without its challenges. The researchers face hurdles along the way:
* Data Quality and Consistency: Historical data is often incomplete or inconsistent due to differing collection methods over the years. The team must carefully harmonize this data to ensure accuracy
* Selection Bias: Since patients were not randomly chosen for the retrospective data, there is a risk of bias that could affect the study’s conclusions
* Recall Bias: Some patients struggle to remember past medical events accurately, making it difficult to verify certain details
* Confounding Variables: Both measured and unmeasured factors in historical data may obscure the true relationship between treatment and outcomes
* Resource Intensiveness: Managing both past and future data requires meticulous planning, coordination, and significant resources.
Despite these obstacles, the ambispective approach provides a richer, more complete picture of disease progression and treatment effectiveness. To ensure scientific rigor and comparability, statistical approaches play a crucial role in mitigating these limitations. In this article, we are discussing the various statistical approaches to overcome these limitations, thereby researchers to gain deeper insights, ultimately contributing to better clinical decision-making and improved patient care.
STATISTICAL CONSIDERATION ON STUDY DESIGN
When designing an ambispective study, several key aspects require careful consideration. Study design and data collection should ensure uniform definitions and consistent data capture across retrospective and prospective periods [Table 1]. Thoughtful integration of retrospective and prospective components is critical to maintain analytic coherence and avoid misclassification or bias.
The statistical considerations in ambispective studies revolve around bias control, missing data management, time-dependent confounding, and appropriate analytical methods. Techniques such as propensity score matching (PSM) and inverse probability weighting (IPW) help address selection bias, while multiple imputation (MI) tackles missing data. Time-dependent Cox models and generalized estimating equations (GEEs) correct for changes in treatment patterns over time, ensuring robust analyses. Furthermore, sensitivity analyses and E-value calculations help strengthen causal inference in the absence of randomization. By integrating advanced statistical techniques, researchers can enhance the validity, reliability, and generalizability of findings in ambispective studies. Another critical consideration is the need for a robust statistical analysis plan that prespecifies endpoints, analytic methods, approaches for missing data, and interim analyses. Incorporating interim analyses in ambispective studies, especially during the prospective phase, allows early assessment of emerging trends or safety signals while maintaining study integrity. The following sections explore key challenges and their statistical solutions identified through various well-conducted studies in greater detail. The key statistical challenges for ambispective studies are:
Selection bias
Leveraging both past records and real-time data collection, ambispective studies provide a unique opportunity to assess treatment outcomes comprehensively. However, this dual approach presents challenges, particularly in managing selection bias that arises from disparities in retrospective data sources and prospective follow-up processes.
In the retrospective component, there is a risk that the cohort does not accurately represent the general population. A significant portion of the data is derived from hospital records, leading to a higher proportion of severely ill patients who sought medical care, while healthier individuals who did not require treatment may be underrepresented. This imbalance introduces systematic bias, potentially distorting conclusions about the treatment’s overall effects. In addition, the absence of randomization in retrospective data poses another challenge. Differences in patient characteristics, such as age, gender, socioeconomic status, and comorbidities, between treated and untreated individuals could introduce confounding effects, making it difficult to isolate the true impact of the treatment from other influencing factors. In the prospective component, researchers have the advantage of actively following patients over time, allowing for more controlled data collection and minimization of missing information. However, selection bias can still arise due to loss to follow-up, differences in treatment adherence, or changes in clinical practice over time.
To address selection bias and enhance the internal validity of observational research, a range of advanced statistical techniques have been developed. Among the most widely used is PSM, which aims to create comparable groups by balancing baseline characteristics between treatment and control cohorts. The process typically involves estimating propensity scores through logistic regression or machine learning algorithms, followed by matching treated and untreated subjects using methods such as nearest-neighbour or calliper matching. After matching, balance diagnostics are conducted to ensure that covariates are evenly distributed between groups, thereby reducing the influence of confounding variables on outcome estimates.
In addition to PSM, IPW is frequently employed to adjust for differential selection probabilities and to enhance the generalizability of findings. This approach involves modelling the probability of treatment or selection using logistic regression, calculating inverse probability weights to adjust for underrepresented groups, and applying these weights in outcome models. When appropriately integrated, PSM and IPW can effectively minimize selection bias and improve the robustness of causal inferences in real-world data analyses. These methodological adjustments enhance the study’s credibility, minimize bias, and improve the reliability of conclusions drawn from the data. Through careful study design and the application of robust statistical techniques, ambispective studies can overcome inherent biases, allowing for more accurate assessments of treatment effects and generating valuable insights to inform clinical decision-making.
Temporal biases
Ambispective cohort studies are inherently vulnerable to temporal biases that may compromise the accuracy of exposure-outcome relationships. These biases arise due to differences in data collection methods across time, particularly between historical and real-time observations. Among the most prominent temporal biases are lead-time bias and recall bias, both of which require careful methodological attention to preserve the validity of study findings.
Lead-time bias occurs when early diagnosis, often resulting from past screening protocols, creates the illusion of extended survival without altering the underlying disease trajectory. This artificially prolonged observation period can lead to a substantial overestimation of treatment efficacy. In ambispective designs, where retrospective and prospective components may operate on different diagnostic timelines, such bias introduces inconsistencies in survival analysis. Lead-time bias has been well-documented in screening studies, particularly in oncology research, for example, in mammography-based breast cancer screening, where earlier detection results in apparent survival gains despite unchanged disease progression. To mitigate lead-time bias, several statistical techniques have been recommended. These include the use of Cox proportional hazards models with time-dependent covariates to account for differences in diagnosis timing. Landmark analysis has also been employed to align patients at a standardized time point postdiagnosis, ensuring comparability of survival estimates. In addition, joint modelling approaches, which integrate longitudinal biomarker data with time-to-event outcomes, have been shown to reduce distortions caused by variations in diagnostic entry points. Together, these strategies enhance the precision of survival analyses by separating genuine treatment effects from artefactual improvements due to early detection.
Recall bias represents another significant challenge in ambispective studies, particularly within the retrospective phase. This bias arises when historical data rely on patient memory, which may be inaccurate or incomplete, especially regarding symptoms, medication adherence, or exposure histories. In contrast, prospective data benefit from real-time documentation, leading to differential accuracy between study phases. Recall bias is a well-recognized limitation in epidemiologic research, notably in case-control and longitudinal cohort designs, where participant recollection may vary depending on health status or outcomes.
To reduce the impact of recall bias, current best practices emphasize reliance on objective data sources, including electronic health records, disease registries, and biomarker measurements. When self-reported data are unavoidable, validation against medical records is recommended to improve data reliability. Furthermore, sensitivity analyses can be employed to evaluate the influence of potential misclassification, while MI techniques help address missing or uncertain retrospective data. The application of probabilistic bias analysis has also gained traction as a means of quantifying and adjusting for recall-related errors, thus enhancing analytical robustness.
By integrating these methodological safeguards, ambispective studies can substantially improve the accuracy and credibility of their findings. Addressing temporal biases through rigorous planning, appropriate statistical modelling, and data validation not only strengthens the internal validity of research outcomes but also supports more reliable evidence generation for clinical decision-making.
Data quality and completeness
Ensuring data quality and completeness represents a critical methodological challenge in ambispective cohort studies, as these designs inherently combine retrospective and prospective data sources with distinct collection practices.
Retrospective data typically extracted from historical medical records, administrative databases, or patient-reported information are often affected by missing laboratory results, incomplete treatment histories, and gaps in follow-up documentation. These limitations may result from selective documentation practices, changes in clinical protocols over time, or inaccuracies in patient recall, all of which can introduce systematic bias into statistical analyses. In contrast, prospective data collection, though more structured, is vulnerable to participant attrition due to consent withdrawal, loss to follow-up, or mortality. To address these concerns, several methodological strategies have been proposed and widely implemented.
* Aligning retrospective and prospective timeframes can be challenging; techniques such as landmark analysis and delayed entry models help standardize baseline (time-zero)
* Retrospective data may suffer from missing or inconsistent data, while prospective data are structured but may have limited follow-up; Multiple Imputation by Chained Equations and sensitivity analyses (e.g., complete-case, worst-/best-case scenarios) are commonly used
* Selection bias may occur when only patients who survive the start of the prospective phase are included; this can be addressed using IPW) and PSM
* Time-dependent confounding arises when covariates or exposures change over time; methods such as time-dependent Cox regression and Marginal Structural Models (MSMs) with IPW are effective
* Informative censoring due to nonrandom dropout in the prospective phase can bias survival estimates; solutions include competing risk models and IPW based on dropout probabilities
* Data heterogeneity due to varied sources and clinical settings may affect comparability; data harmonization protocols, random-effects models, or meta-analytic approaches help account for this variability
* Small sample sizes in retrospective or prospective subgroups limit power; Bayesian hierarchical models and simulation studies are used to estimate and boost statistical power
* Lack of randomization increases susceptibility to residual confounding; E-value calculations assess robustness to unmeasured confounding, and instrumental variable analysis is used when valid instruments are available.
By integrating these strategies, including imputation, survival modelling, and sensitivity analyses, ambispective studies can substantially improve data reliability and minimize bias. A systematic approach to addressing data quality not only enhances the credibility of statistical inference but also ensures that ambispective designs contribute valid and generalizable evidence to support clinical decision-making and policy development.
Integration of retrospective and prospective data
The integration of retrospective and prospective data forms the backbone of ambispective research designs, offering a unique opportunity to leverage both historical and real-time patient information. However, differences in data origin, completeness, and structure necessitate thoughtful analytical strategies to ensure consistency and validity across the study continuum. To address these discrepancies, sensitivity analyses play a vital role in examining how assumptions related to missing or imprecise information may influence study outcomes. This approach allows for a transparent evaluation of potential bias introduced by incomplete historical records or attrition in prospective follow-up. Im addition, the nested nature of ambispective data, where longitudinal observations is layered upon an existing retrospective cohort, calls for the application of hierarchical models (also known as multilevel models). These models effectively handle data structures that involve repeated measures or clustering by accounting for variability at multiple levels, thereby producing more accurate and generalizable inferences.
Time-dependent confounding, where variables evolve alongside the exposure and outcome, poses additional challenges. This is particularly relevant when data spans multiple years or involves chronic conditions. To address such dynamic relationships, MSMs and dynamic regression methods are recommended. For time-to-event outcomes, tools such as Kaplan-Meier estimators and Cox proportional hazards models are commonly used. When analyzing longitudinal data, GEE and mixed-effects models effectively account for intra-individual variability and repeated measures.
To improve causal inference despite inherent biases, methods like instrumental variable analysis and Bayesian frameworks offer structured approaches to handle unmeasured confounding and incorporate prior knowledge. Through structured integration of historical and prospective data streams and by employing advanced statistical techniques, ambispective cohort studies can yield robust, clinically relevant insights, especially in fields where long-term follow-up and real-world evidence are vital.
Statistical power and sample size estimation
Ambispective studies present unique challenges in power estimation due to the presence of censored data, which commonly arises from loss to follow-up, withdrawal of consent, or death before the study completion. This censoring complicates traditional power calculations, particularly for time-to-event outcomes. In such designs, a portion of data is collected retrospectively, where event occurrence may already be known, while the prospective component continues to accrue data over time, introducing nonuniform follow-up durations across participants. Sample size determination must account for parameters such as expected effect size, baseline event rate, duration of retrospective follow-up, planned prospective follow-up, accrual and attrition rates, and the type of primary outcome. To address these challenges, simulation-based approaches and adaptive sample size recalculations are increasingly employed. These methods account for varying accrual patterns, dropout rates, and anticipated censoring proportions, offering more realistic power estimations. In addition, survival analysis techniques such as Kaplan-Meier estimation and Cox proportional hazards modelling with time-dependent covariates are used to incorporate censored observations without biasing the statistical inference. Furthermore, competing risk models and MI for censored covariates improve the robustness of power and effect size estimations, ensuring that the analysis reflects the complex temporal structure of ambispective designs.
Small sample sizes for subgroup analysis
Ambispective studies frequently encounter constraints related to small sample sizes, especially when focusing on rare diseases or subpopulations. The hybrid nature often leads to fragmented data sources, incomplete follow-up, and varying degrees of data quality all of which limit the available analysable sample size.
Small sample sizes reduce statistical power, making it more difficult to detect true associations or treatment effects. This limitation increases the risk of type II errors, where potentially meaningful findings may go undetected. Moreover, with complex modelling strategies, especially those adjusting for time-dependent covariates or handling missing data, the likelihood of overfitting increases significantly. Overfitting occurs when models become too tailored to the specific dataset, capturing noise rather than generalizable patterns, which undermines external validity and reproducibility. To address these challenges, researchers are advised to:
* Reduce model complexity
* Ensure an adequate sample size-to-predictor ratio
* Avoid including spurious or weak predictors
* Apply regularization techniques such as Least Absolute Shrinkage and Selection Operator or ridge regression; and
* Use robust validation methods such as cross-validation or bootstrapping.
Adaptive design strategies can also enhance the validity of small sample subgroup analyses in ambispective studies. These designs allow researchers to refine their subgroup definitions and statistical approaches as additional prospective data become available.
Heterogeneity
Heterogeneity in ambispective cohort studies arises from variations in patient characteristics, treatment responses, and data collection across retrospective and prospective phases. Such heterogeneity complicates interpretation but also enhances opportunities to understand treatment effects more comprehensively. Previous studies have shown that ambispective designs, though limited in number, provide a more realistic assessment of clinical algorithms compared to retrospective-only models. Applications have included diabetic retinopathy grading, breast cancer metastasis detection, wrist fracture identification, and colonic polyp detection. Differences in baseline risk further drive heterogeneity, influencing treatment effectiveness. For instance, higher-risk patients show greater benefits from interventions, as seen in invasive coronary procedures and diabetes prevention programs. This supports the use of risk-based approaches to evaluate heterogeneity of treatment effects (HTE), as emphasized by the predictive approaches to treatment effect heterogeneity statement. However, subgroup analyses often lack power and fail to capture the complexity of HTE across multiple variables. Ambispective designs offer a broader view by incorporating both historical and forward-looking data to uncover these nuances. Standardized frameworks such as the OMOP Common Data Model and OHDSI improve consistency across data sources, enabling large-scale collaborative research. The OHDSI network, for example, has demonstrated the feasibility of such models in evaluating antihypertensive treatments through the LEGEND-HTN study. To further account for heterogeneity, meta-regression and mixed-model techniques allow for analysis across subgroups defined by multiple biomarkers or variables. Meta-regression enables the quantification of variability across subgroups and helps identify potential effect modifiers by incorporating study-level covariates into the analysis. This approach is particularly useful for integrating retrospective and prospective components, where baseline characteristics and treatment responses may differ. Stratified analyses, on the other hand, allow for evaluation of treatment effects within predefined subgroups such as risk categories or biomarker-defined strata, thereby enhancing the interpretability of heterogeneous outcomes. These methods provide a structured framework to account for inherent variability and improve the robustness and generalizability of study findings, especially in complex ambispective designs where patient populations and data quality may vary over time.
Time-dependent variables
In ambispective cohort studies, accounting for temporal dynamics is critical, as patient characteristics, exposures, and outcomes often evolve over time. Time-varying covariates enable a nuanced understanding of these dynamics, enhancing the precision of treatment effect estimates and supporting robust longitudinal modelling across retrospective and prospective phases. Such variables are especially relevant when exposures or confounders change during follow-up, as seen in clinical oncology or lifestyle-related risk factors like smoking. A key analytical challenge arises when confounders are time-dependent, affecting both the outcome and future exposure levels, and may themselves be influenced by prior treatment, thus functioning as both confounders and intermediates. Directed acyclic graphs provide a conceptual framework to depict these relationships, distinguishing between static confounding structures and those arising over time. To address this complexity, time-dependent Cox models and joint modelling approaches are often employed. These techniques help appropriately model the dynamic associations between covariates and outcomes, particularly when internal (dependent on survival status) and external (fixed) covariates are present. Mixed-effects models are another valuable approach, especially for repeated measures data, as they incorporate both fixed and random effects, capturing subject-specific variability and handling incomplete data typical of ambispective designs. The inclusion of time-varying covariates and appropriate analytical frameworks is essential to mitigate bias, improve generalizability, and provide clinically relevant insights in ambispective research.
Confounding factors
Confounding, particularly from time-varying factors, poses a substantial challenge in ambispective cohort designs. A confounder is a variable associated with both the exposure and the outcome, potentially distorting observed associations if unaccounted for. In epidemiological research, failure to adjust for such variables can lead to misleading conclusions. For example, interpreting coffee consumption as a risk factor for lung cancer without accounting for smoking habits is a classic confounding variable. This misinterpretation illustrates phenomena such as Simpson’s paradox, where aggregated data obscure or reverse underlying associations. To minimize confounding effects during analysis, two principal methods are employed: stratification and multivariate modelling. Stratification involves creating subgroups within which confounders are evenly distributed, followed by application of estimators like Mantel-Haenszel to yield adjusted associations. However, stratification becomes impractical when numerous or finely categorized confounders are present. In such cases, multivariate models are preferred, offering simultaneous adjustment for multiple covariates and improved handling of complex data structures. Ambispective designs further complicate confounding control due to the blending of retrospective and prospective data, often accompanied by loss to follow-up and censoring. Rigorous statistical handling of these issues is essential to preserve validity and minimize bias in outcome estimation.
Lost to follow up and censoring
Missing data due to patient withdrawal is a common challenge in longitudinal and ambispective studies. Participants may drop out for various reasons, including adverse events, lack of improvement, early recovery, or unrelated personal factors, leading to potential biases if data are analyzed only from those who complete the study. These incomplete observations are typically addressed through censoring techniques in survival analysis. Right censoring occurs when the event of interest has not occurred by the end of the study or is unobserved due to dropout. Left censoring, although less common, arises when the event occurs before the individual enters the study, with the exact time unknown. To handle these issues, survival data are often analyzed using methods such as the Kaplan-Meier estimator, which provides unadjusted survival probabilities over time. The resulting step-function survival curves visualize the probability of surviving beyond specific time points, with vertical drops marking observed events and symbols (e.g., asterisks) indicating censored observations. Confidence intervals and bands are frequently added to assess the precision of survival estimates and group comparisons are facilitated by plotting multiple curves on the same graph. In ambispective designs, where both retrospective and prospective data coexist, appropriate survival methods are essential for valid estimation, particularly in the presence of censoring and loss to follow-up.
CONCLUSION
Ambispective cohort studies offer a unique advantage by leveraging both retrospective and prospective data to evaluate long-term outcomes and treatment effects. However, careful attention must be paid to study design, interim analysis, handling of time-varying covariates, confounding, missing data, and potential temporal biases. Employing appropriate statistical methods, including time-dependent models and propensity score approaches, enhances the validity of findings. Importantly, engaging multidisciplinary expertise such as statisticians, therapeutic area specialists, and data managers during the study design phase is essential to preempt data-related issues and ensure accuracy and precision in the generated evidence. With rigorous planning and execution, ambispective studies can provide valuable real-world insights applicable to clinical decision-making.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.
